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A short running head: 
OMERACT methodology: instrument selection  
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8Title: Instrument selection using the OMERACT Filter 2.1: The OMERACT Methodology 
Abstract
Objective:   Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process 
used for core outcome measurement set selection to add rigour and transparency in decision 
making. This paper describes OMERACTs methodology for instrument selection.  
Methods:  We presented instrument selection processes, tools, and reporting templates at 
OMERACT 2018, introducing the concept of 3 pillars, 4 questions, 7 measurement properties, 1 
answer. Truth, Discrimination and Feasibility are the three original OMERACT pillars. Based 
on these, we developed four signaling questions. We introduced the Summary of Measurement 
Properties (SOMP) table which summarizes the seven measurement properties: Truth (domain 
match, construct validity), Discrimination (test-retest reliability, longitudinal construct validity 
(responsiveness), clinical trial discrimination, thresholds of meaning), and Feasibility. These 
properties address a set of standards which, when met, answer the one question: Is there enough 
evidence to support the use of this instrument in clinical research of the benefits and harms of 
treatments in the population and study setting described?    The OMERACT Filter 2.1 was 
piloted on two instruments by the Psoriatic Arthritis Working Group
Results:  The methodology was reviewed in a full plenary session and facilitated breakout 
groups.   Tools to facilitate retention of the process (i.e., The OMERACT Way) were provided.  
The two instruments were presented and the recommendation of the working group was 
endorsed in the first OMERACT Filter 2.1 Instrument Selection votes.  
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9Conclusion:  Instrument Selection using OMERACT Filter 2.1 is feasible and is now being 
implemented.   
Introduction 
Core outcome sets (COS) are increasingly recognized as a minimum set of outcomes that 
will be measured across all clinical trials in a given field in order to facilitate comparisons of 
interventions and meta-analyses, and to avoid selective outcome reporting bias (1).  OMERACT 
(Outcome Measurement in Rheumatology) has promoted and supported the development of COS 
since its inception in 1992 (2). Although the main focus has been in the area of musculoskeletal 
disorders and rheumatologic conditions (3), it has also found application in other fields (4,5). 
OMERACT divides the task of creating a COS into two components: first, determining 
what needs to be measured (Core Domain Sets) and second, deciding how to measure each of the 
domains, also referred to as instrument selection.  This in turn leads to a Core Outcome 
Measurement Set, when there is at least one outcome measurement instrument identified for each 
domain.  In 2012, OMERACT voted to revise their processes to recognize both the growth of the 
organization and of the literature available on measurement properties of any given outcome 
measurement instrument. The creation of a Core Domain Set was outlined by Boers et al in 2014 
(6) and is expanded on in this issue in two companion papers (7, 8).  The purpose of this paper is 
to describe a data-driven, evidence-based process for the instrument selection process and the 
OMERACT Filter 2.1 methodology.  
Methods
Foundations of the OMERACT Filter: Three pillars, four questions, seven measurement 
properties, one answer.  
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Truth, Discrimination, and Feasibility are the pillars of the OMERACT Filter (9).  Truth 
refers to if the measures scores can be shown to be truthful, measuring what was intended.  
Discrimination: Does the measure discriminate between situations of interest  such as between 
treatment arms in a clinical trial.  Finally, Feasibility answers very practical questions about the 
practicality of using the tool  time, cost, and burden.  Together, these three pillars describe a set 
of standards which, when met, answer the one question: Is there enough evidence to support the 
use of this instrument in clinical research of the benefits and harms of treatments in the 
population and study setting described?  
In OMERACT Filter 2.1, we recognized that the three pillars of the original OMERACT 
Filter are best represented by four signaling questions (Figure 1a).  Two questions split the Truth 
pillar into a practical appraisal of the instrument and its content with Is it a match with the target 
domain?, and more data-driven, hypothesis-testing assessment of the instruments scores with 
Do the numeric scores make sense (i.e., are the scores relating to other measures or the testing 
situation in a way it should if it measures the domain well?)?. Can it discriminate between 
groups of interest? reflects the Discrimination pillar, assessing whether the instrument captures 
differences between treatment and control groups found in clinical trials.  The signaling question, 
Is it practical to use? i.e., in terms of cost, burden, and access, reflects the Feasibility pillar.
In practice, when this method is used to assess an instrument, the signaling questions are 
slightly reordered, putting practical appraisals of concept match and feasibility ahead of the 
review of the evidence available on the more data-driven features of testing truth and 
discrimination. This saves time and resources as it allows instruments to be set aside if they are 
not capturing the target domain concept or are not feasible for use in the target application. This 
reordering is seen in the bottom of Figure 1b. 
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<<FIGURE 1A >>
<<FIGURE 1B >>
The four signaling questions and the traffic light ratings they received are linked on the 
OMERACT Filter 2.1 Instrument Selection Algorithm (OFISA) (Figure 2).  Ratings are 
completed for each question and then combined into an overall rating for the instrument. Red 
always means stop, do not continue, Amber means a caution is raised, but you can continue, 
and Green means go, this question is definitely answered affirmatively.  White circles indicate 
an absence of evidence leaving working groups to decide if they wish to create the evidence 
needed, or consider it a gap so further evaluation should stop because evidence is missing.  Once 
all four questions are answered, based on this evidence the Working Group recommends an 
overall level of endorsement (bottom Figure 2).   
 << FIGURE 2 >>
Instrument Selection Using OMERACT Methodology  
The step by step process of OMERACTs instrument selection methodology will be described 
briefly here following the steps illustrated in Figure 3, How to choose an instrument the 
OMERACT Way.  A detailed description of these steps is available in the OMERACT 
Handbook (10). 
<<FIGURE 3>>
1.  Revisit the Domain Definition.
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Prior to embarking on any instrument selection process, working groups should review the 
domain(s) each instrument is trying to capture. This is done making use of the definitions 
described in the OMERACT Onion document (7) and the OMERACT Filter 2.1 Framework (8).  
2. Find candidate instruments.   
Creating a new instrument is a difficult task, and groups often can identify an existing 
instrument(s) by searching the literature (11-13) or speaking to experts in the field.   
3. Is the instrument a match for the target domain?
Working groups then address the signaling questions described above.  Armed with the domain 
definition and the candidate instrument, working groups can identify whether the instrument or 
outcome measure (terms used here interchangeably) matches the intended target domain. This is 
done by seeking the experiences of those who will respond to the instrument.  Working groups 
should talk to people, particular those with the lived experience of the disease and domain, to see 
if the instrument captures the breadth and depth of the experience.  Templates for surveying 
respondents are provided in the OMERACT Instrument Selection Workbook 
(www.omeract.org/resources).   Available data can be used to examine if the response 
distribution for the scale are appropriate.  High ceiling or floor effects in people experiencing the 
domain (i.e., physical limitation) could flag that the scale will not detect the differences of 
interest in the relevant population, or could also reflect an expected level for certain indices or 
aggregate scores (14).  Cognitive interviews can be used at this stage to examine how items are 
interpreted; for example, whether people, particularly those with the lived experience of the 
disease and domain, would prefer different question stems, anchors, or response options (15).  
4 Is it feasible to use this outcome measure? 
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Feasibility is a practical assessment of the burden of use, where burden could be cost, time, 
equipment, personal burden for the respondent (e.g., language, health literacy) or administrator 
(e.g., required training), the interpretability of the scores, and other similar considerations (16).   
Some of these features can be assessed using surveys or checklists compiled with working group 
and stakeholder input (see OMERACT Instrument Selection Workbook 
(www.omeract.org/resources)) or through other structured techniques in focus groups or nominal 
group processes.   Occasionally assessments of feasibility (time to complete the assessment or 
survey, complexity of language, or technical demands of interpreting imaging results) are 
published in the literature, however OMERACT will also accept the appraisal of the working 
group for the answer to this question.   
5. Narrowing the number of candidate measures.  
At the next stage, the working group determines whether there is a clear match of an outcome 
measurement instrument with the target domain and whether the instrument is feasible for use in 
the intended setting.  An instrument that is not a good match to the target domain definition or is 
not feasible should be set aside, as these shortcomings are unlikely to be easily addressable.   
This is a key step in the process and often leads to a shortened list of candidate instruments.   
Working groups are asked to record the level of agreement within their working group and any 
comments made when either proceeding or setting aside an outcome measurement instrument at 
this point.    
6. Gather evidence for the next two signaling questions. 
 The last two questions (Do the numeric scores make sense? and Can it discriminate between 
groups of interest?) are represented by five additional measurement properties that require data-
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oriented answers: construct validity (scores relate to other known measures in a way that is 
consistent with the underlying domain of interest), test-retest reliability (no change in score when 
patients are stable, estimate of day to day variability), longitudinal construct validity 
(responsiveness) (ability to detect change when it has occurred), ability to discriminate in a 
clinical trial (specific ability to detect change between arms in a clinical trial), and thresholds of 
meaning (benchmarking scores and changes in score for interpretation) (as seen in Figure 1b). 
The evidence to support performance of an instrument on each of these properties is based on the 
growing body of literature on measurement properties (17, 18).  In response to this, OMERACT 
Filter 2.1 has adopted standard systematic review techniques as described by Slavin (19) to 
capture and process available literature.  Slavin describes the stages of such a review as:  (i) 
gathering the evidence, (ii) appraisal of quality of the evidence, (iii) data extraction, and (iv) 
synthesis of findings.   The result is parallel systematic reviews, one for each of the measurement 
properties of interest.   The process is described briefly here and in more detail in the 
OMERACT Handbook (10). 
i) Gathering the evidence on the measurement properties
Systematic literature searches are conducted with the support of library scientists and standard 
search term templates available to working groups.  The search terms focus on the measurement 
properties and the relevant patient population for the outcome measure.  Searches are run often 
by a librarian or information scientist; the working group screens the titles and abstracts to see if 
they match the instrument and to ensure they are about measurement properties.   Positive or 
possible articles are obtained for fulltext review of their relevance, and to see which 
measurement properties are addressed in that article.   Working groups at this point begin 
building their Summary of Measurement Property (SOMP) table, where the relevant articles are 
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listed (see Table 1) and the measurement properties covered are recorded.  Importantly, only the 
seven measurement properties relevant to the application of an existing measure in a clinical trial 
are reviewed.  Tracking of the yield and selection of articles should be rigorous and reported in a 
PRISMA flow chart (http://www.prisma-statement.org/).   
Evidence for OMERACT endorsement can also be created by the working groups by conducting 
a study to address any gaps found in the SOMP table.  The methods and results of these studies 
are independently reviewed by at least two members of the Technical Advisory Group of 
OMERACT (https://omeract.org/tag) before they are considered for inclusion.  
ii)   Quality assessment  
All evidence, both that found in the literature and new evidence created by the working group, 
undergoes quality assessment.   Several quality assessment tools exist in the literature though 
few specifically address our goal of looking to exclude those with critical flaws that could lead to 
a risk of bias in the estimation of the measurement property performance.  COSMIN (four point 
checklist version) is one frequently used critical appraisal tool for measurement studies (20).  
Only certain items in the checklist offer a Poor response category.  This rating is reserved to 
indicate the situations in which the methods reported are flawed enough that this evidence should 
not be included in the review due to risk of bias.  In 2015, we worked with the COSMIN and 
reworded these specific items into a positive, dichotomized response to capture if the study 
reported good methods, and had successfully avoided a risk of bias as indicated in that poor 
rating.  Focusing only on measurement properties needed for OMERACT Filter 2.1 we added 
two measurement properties important to OMERACT which were not in COSMIN, clinical trial 
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discrimination and thresholds of meaning, to produce the COSMIN-OMERACT Good Methods 
Checklist found in our current OMERACT Handbook (10). 
Good Methods Checklist items are assessed independently by two persons, and agreement is 
sought between them.  Any newly created evidence has the Good Methods check done by two 
members of the technical advisory group independent of the working group.  This is rated in 
traffic light format again and the colour entered in the cells of the SOMP table (Table 1), with 
green or amber indicating good methods, and red indicating a high risk of bias. Only studies that 
have passed the Good Methods Check move to the next stage of extracting information and the 
results of the measurement property tests.
iii)  Data extraction
The results of the testing of measurement properties are extracted from the publications and 
placed into a narrative summary of the testing procedures, study characteristics, and results.  
Enough detail is provided in a data extraction table to allow a user of the data to follow the logic 
and rationale for the decisions made.  Results are compared to international recommendations for 
acceptable performance in terms of results of a measurement property study.   In the SOMP 
table, a + is placed for a positive performance, +/-for equivocal, and  for inadequate 
performance.   
iv) Synthesis 
The next step is the synthesis of evidence that has been appraised as at least adequate (green or 
amber colour) quality evidence, into a rating of the performance of the instrument for each of the 
seven measurement properties in the SOMP.  Both published and new studies are considered.   
Our synthesis methods are based on the practices of several groups in different fields, (4, 20, 21) 
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which emphasize the importance of having Quality information (using studies with good 
methods); Quantity (at least two good methods studies), showing Consistency of the findings 
across these pieces of evidence; and adequate Performance in the tests of that measurement 
property.  Combining these elements, Quality, Quantity, Consistency and Performance (QQC-P), 
a synthesis statement is made for each measurement property.  The working group then decides 
on a recommendation based on their good quality evidence.  
3.7  Identify the winners (best instruments).   In the last row of the SOMP, the working group 
identifies the instrument(s) that have passed the Filter 2.1 requirements with either a green 
(endorsed) or amber (provisionally endorsed) rating at the instrument level.  All amber rated 
instruments must have a clearly defined research agenda of what additional work is needed to 
bring this instrument to a green for full endorsement.   
3.8 Bring it to a vote   
Core to the OMERACT decision-making process is engaging the OMERACT community in 
evaluating the results of the instrument selection process and seeking a vote of support from that 
community as to its rigour and conclusions.   When evidence about an instrument is gathered, 
and a decision is made as to the level of endorsement the Working Group thinks it should 
receive, the group will bring this to the OMERACT Technical Advisory Group for review. If the 
evidence is deemed to be of sufficient quality the group may have an opportunity to present their 
findings at a full plenary session, called a workshop, during a face-to-face OMERACT biennial 
meeting.  Seventy percent agreement by the OMERACT community (voting at that session) will 
be considered support for the endorsement.  
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In  addition to the guidance in Instrument Selection Chapter the OMERACT Handbook (10), the 
OMERACT Master Checklist and Workbook for Instrument Selection have been developed to 
help Working Groups keep track of their progress and to ensure full and transparent reporting. 
These resources are available on the OMERACT website (https://omeract.org/resources).  No 
ethics approval was required for this work as it is did not involve human subjects.
<<TABLE 1>>
Results of the initial application of the OMERACT Filter 2.1 Instrument Selection 
Algorithm 
At OMERACT 2018, a presentation was given in the opening plenary to describe the instrument 
selection process delineated above, and in the OMERACT handbook.  The OMERACT methods 
for instrument selection figure, known as the The OMERACT Way, and the OMERACT Filter 
2.1 Instrument Selection Algorithm were provided for reference throughout the meeting.   The 
Psoriatic Arthritis Working Group presented two instruments for endorsement by the 
OMERACT community, becoming the first group to move through the Filter 2.1 Instrument 
Selection process.  The first was the 66-joint swollen joint count and 68-joint tender joint count 
(SJC66/TJC68 joint counts) as instruments to reflect the domain of musculoskeletal disease 
activity in the peripheral joints. The second was the Psoriatic Arthritis Impact of Disease 
questionnaire (PsAID12) for the measurement of the core domain psoriatic arthritis-specific 
Health Related Quality of Life.  The final recommendations of the Working Group were 
presented at the plenary session, where they highlighted strengths and weaknesses of the two 
candidate instruments. Both the SJC66/TJC68 and PsAID12 achieved consensus (i.e. 70 % or 
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greater vote) by the OMERACT community and were the first instruments to be passed through 
OMERACT Filter 2.1 as fully and provisionally endorsed measures, respectively (22, 23). 
Discussion 
The OMERACT Filter 2.1 revisions address instrument selection within an evolving paradigm of 
measurement instrument assessment. These methods emphasize the increasing need for an 
outcome measures scores to have enough evidence to engender confidence in its use in a 
particular setting.  The process has its foundation in the original OMERACT pillars of Truth, 
Discrimination, and Feasibility that are still critical requirements for instruments to meet, and 
adds systematic approaches to gathering, appraising and synthesizing evidence on the 
performance of the instrument.  The OMERACT Technical Advisory Group will continue to 
work with OMERACT Working Groups to operationalize the instrument selection process to 
ensure we are achieving the goal of transparent, rigorous, evidence-based instrument selection 
for Core Outcome Measurement Sets.  
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Figure Legends
[Figure 1].  1A) The three OMERACT Filter Pillars of Truth, Discrimination and Feasibility 
(circles) and the signaling questions involved in each.   Measurement properties required to 
answer each signaling questions (7 in total) are listed.  1B) Pragmatic reordering of signaling 
questions, separating the two Truth questions and inserting Is it practical to use? (Feasibility) 
between.  This order now reflects increasing investment of time and effort, and reflect decision 
making nodes.  If there is a no to either domain match or feasibility, there is no need to 
continue to the more difficult stage of finding or creating evidence of the other properties.   MID 
= minimal important difference, PAS = patient acceptable state.
[Figure 2].  OMERACT Filter 2.1 Instrument Selection Algorithm (OFISA).  The four signaling 
questions are linked to a results column (traffic light ratings), and a renewed emphasis on the 
setting aside of instruments that receive a RED rating for either of the first two questions.  
Amber and Green continue to the last two signaling questions, though the former with care and 
caution.
[Figure 3]. The OMERACT Way flowchart describing the step by step process of OMERACTs 
instrument selection methodology.  
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Table Legend.
Table 1.  OMERACT Summary of Measurement Properties (SOMP) Table.   A summary of the 
work leading up to the working groups decision about an instrument and whether it has passed 
the OMERACT Filter of Truth, Discrimincation and Feasibility. In this table fictitious studies are 
shown for demonstration only.   All selected articles are listed and the measurement properties 
they studied noted.  Colour reflects the good methods check with green saying good avoidance 
of risk of bias, amber meaning some concerns, and red being a red flag for risk of bias.  Only 
amber and green cells are used in synthesis.  + = surpasses standard for good performance, - = 
does not surpass performance and +/- equivocal findings.  
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 1A. The three OMERACT Filter Pillars of Truth, Discrimination and Feasibility (circles) and the signaling 
questions involved in each.   Measurement properties required to answer each signaling questions (7 in 
total) are listed.   
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 1B. Pragmatic reordering of signaling questions, separating the two Truth questions and inserting Is it 
practical to use? (Feasibility) between.  This order now reflects increasing investment of time and effort, 
and reflect decision making nodes.  If there is a no to either domain match or feasibility, there is no need 
to continue to the more difficult stage of finding or creating evidence of the other properties.   
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 Figure 2.  OMERACT Filter 2.1 Instrument  lection Algorithm (OFISA).  The four signaling questions are 
linked to a results column (traffic light ratings), and a renewed emphasis on the setting aside of instruments 
that receive a RED rating for either of the first two questions.  Amber and Green continue to the last two 
signaling questions, though the former with care and caution. 
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Figure 3. The OMERACT Way for instrument selection flowchart describing the step by step process of 
OMERACTs instrument selection methodology.  
Page 29 of 30
A
cc
ep
te
d
 A
rt
ic
le
T
h
is
 a
cc
ep
te
d
 a
rt
ic
le
 i
s 
p
ro
te
ct
ed
 b
y
 c
o
p
y
ri
g
h
t.
 A
ll
 r
ig
h
ts
 r
es
er
v
ed
.
 Rheumatology
The Journal of on April 2, 2019 - Published by www.jrheum.orgDownloaded from 
 Table 1.  OMERACT Summar f Measurement Properties (SO 	
   A summr of the work leading up 
to the working grs decision about an instrument and whether it has passed the O  
r of Truth, 
Discrimincation and 

sibil

 In this table fictitious studies are shown for demonstration o
  All selected 
articles are listed and the measurement properties 

 studied noted.  


our reflects 

 
g
d methods 
check th green saog gy avoidance of risk of bias, amber meaning some concerns, and red being a 
red flag for risk of bias.  Onl amber and green cells are used in sosis.   surpasses standard for good 
performance, ff

 does not surpass performance ao
y 
nff fi

ivocal findings.   
254x190mm (96 x 96 DPI) 
Page 30 of 30
A
cc
ep
te
d
 A
rt
ic
le
T
h
is
 a
cc
ep
te
d
 a
rt
ic
le
 i
s 
p
ro
te
ct
ed
 b
y
 c
o
p
y
ri
g
h
t.
 A
ll
 r
ig
h
ts
 r
es
er
v
ed
.
 Rheumatology
The Journal of on April 2, 2019 - Published by www.jrheum.orgDownloaded from 
